Here are the 424B prospectus supplements from Abeona Therapeutics Inc. (ABEO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ABEO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ABEO filings page.
Abeona Therapeutics Inc. filed a prospectus supplement updating a previously effective resale registration for up to 15,219,758 shares of common stock. The update reflects the assignment of 760,870 Common Warrants from Point72 Associates, LLC to SILV Fund, Ltd., without changing the aggregate number of registered shares.
The company will not receive proceeds from any resale of shares by the selling stockholders, but will receive cash proceeds from any warrant exercises. Abeona's common stock trades on The Nasdaq Capital Market under the symbol ABEO, and the closing price on July 7, 2026 was $6.55 per share. Investors are directed to the incorporated risk factors and reports for a detailed discussion of risks.